Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Neuroprotective agents: cannabinoids.

Sánchez AJ, García-Merino A.

Clin Immunol. 2012 Jan;142(1):57-67. doi: 10.1016/j.clim.2011.02.010. Epub 2011 Mar 21. Review.

PMID:
21420365
[PubMed - indexed for MEDLINE]
2.

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.

Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D.

J Neuroimmunol. 2008 Jan;193(1-2):120-9. Epub 2007 Nov 26.

PMID:
18037503
[PubMed - indexed for MEDLINE]
3.

Cannabinoids and experimental models of multiple sclerosis.

Kubajewska I, Constantinescu CS.

Immunobiology. 2010 Aug;215(8):647-57. doi: 10.1016/j.imbio.2009.08.004. Epub 2009 Sep 17. Review.

PMID:
19765854
[PubMed - indexed for MEDLINE]
4.

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.

Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J.

Neurobiol Dis. 2005 Nov;20(2):207-17.

PMID:
16242629
[PubMed - indexed for MEDLINE]
5.

Cannabinoid system and neuroinflammation: implications for multiple sclerosis.

Correa F, Docagne F, Mestre L, Loría F, Hernangómez M, Borrell J, Guaza C.

Neuroimmunomodulation. 2007;14(3-4):182-7. Epub 2007 Dec 5. Review.

PMID:
18073512
[PubMed - indexed for MEDLINE]
6.

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.

García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J.

Brain Res. 2007 Feb 23;1134(1):162-70. Epub 2006 Dec 28.

PMID:
17196181
[PubMed - indexed for MEDLINE]
7.

Role of CB2 receptors in neuroprotective effects of cannabinoids.

Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA.

Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S91-6. doi: 10.1016/j.mce.2008.01.001. Epub 2008 Jan 17. Review.

PMID:
18291574
[PubMed - indexed for MEDLINE]
8.

Therapeutic potential of CB2 targeting in multiple sclerosis.

Docagne F, Mestre L, Loría F, Hernangómez M, Correa F, Guaza C.

Expert Opin Ther Targets. 2008 Feb;12(2):185-95. doi: 10.1517/14728222.12.2.185 . Review.

PMID:
18208367
[PubMed - indexed for MEDLINE]
9.

Role of cannabinoids in multiple sclerosis.

Zajicek JP, Apostu VI.

CNS Drugs. 2011 Mar;25(3):187-201. doi: 10.2165/11539000-000000000-00000. Review.

PMID:
21323391
[PubMed - indexed for MEDLINE]
10.

Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis.

Hasseldam H, Johansen FF.

Neuroimmunomodulation. 2010;17(4):252-64. doi: 10.1159/000290041. Epub 2010 Mar 5.

PMID:
20203531
[PubMed - indexed for MEDLINE]
11.

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML.

J Neurosci. 2005 Feb 23;25(8):1904-13.

PMID:
15728830
[PubMed - indexed for MEDLINE]
Free Article
12.

Cannabinoids and neuroprotection.

Grundy RI, Rabuffetti M, Beltramo M.

Mol Neurobiol. 2001 Aug-Dec;24(1-3):29-51. Review.

PMID:
11831553
[PubMed - indexed for MEDLINE]
13.

Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.

Liblau R.

J Neurol Sci. 2009 Dec;287 Suppl 1:S17-23. doi: 10.1016/S0022-510X(09)71296-1.

PMID:
20106343
[PubMed - indexed for MEDLINE]
14.

The use of cannabinoids in multiple sclerosis.

Teare L, Zajicek J.

Expert Opin Investig Drugs. 2005 Jul;14(7):859-69. Review.

PMID:
16022575
[PubMed - indexed for MEDLINE]
15.

The seek of neuroprotection: introducing cannabinoids.

Martínez-Orgado J, Fernández-López D, Lizasoain I, Romero J.

Recent Pat CNS Drug Discov. 2007 Jun;2(2):131-9. Review.

PMID:
18221224
[PubMed - indexed for MEDLINE]
16.

The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation.

Correa F, Mestre L, Molina-Holgado E, Arévalo-Martín A, Docagne F, Romero E, Molina-Holgado F, Borrell J, Guaza C.

Mini Rev Med Chem. 2005 Jul;5(7):671-5. Review.

PMID:
16026313
[PubMed - indexed for MEDLINE]
17.

Cannabinoids and neuroprotection in motor-related disorders.

de Lago E, Fernández-Ruiz J.

CNS Neurol Disord Drug Targets. 2007 Dec;6(6):377-87. Review.

PMID:
18220777
[PubMed - indexed for MEDLINE]
18.

Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection.

Witting A, Chen L, Cudaback E, Straiker A, Walter L, Rickman B, Möller T, Brosnan C, Stella N.

Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6362-7. Epub 2006 Mar 29.

PMID:
16571660
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

[The role of endocannabinoid system in physiological and pathological processes in the eye].

Nadolska K, Goś R.

Klin Oczna. 2008;110(10-12):392-6. Review. Polish.

PMID:
19195174
[PubMed - indexed for MEDLINE]
20.

Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis.

Berrendero F, Sánchez A, Cabranes A, Puerta C, Ramos JA, García-Merino A, Fernández-Ruiz J.

Synapse. 2001 Sep 1;41(3):195-202.

PMID:
11391780
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk